Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
N/A Nab-paclitaxel Gastrointestinal cancer Do not reimburse Complete
N/A everolimus Renal angiomyolipoma associated with tuberous sclerosis Reimburse with clinical criteria and/or conditions Complete
N/A panitumumab Left-sided metastatic colorectal cancer (mCRC) Reimburse with clinical criteria and/or conditions Complete
N/A Pembrolizumab Melanoma (Skin) Reimburse with clinical criteria and/or conditions Complete
N/A Nivolumab and Ipilimumab Melanoma (Skin) Reimburse with clinical criteria and/or conditions Complete
N/A Nab-paclitaxel Solid tumours Reimburse with clinical criteria and/or conditions Complete
N/A dimethyl fumarate Multiple Sclerosis (MS) Active
N/A teriflunomide Multiple Sclerosis (MS) Active
N/A nivolumab ipilimumab Melanoma Active
N/A imiquimod Gynecological cancers Withdrawn
N/A trametinib Gynecological cancers Active
N/A Enzalutamide Genito-urinary cancer (prostate cancer) Complete
N/A nab-paclitaxel Gastrointestinal cancer Reimburse with clinical criteria and/or conditions Complete
N/A Dabrafenib trametinib Head and neck cancer Active
N/A regorafenib Metastatic osteosarcoma Active
N/A blinatumomab Acute lymphoblastic leukemia, pediatrics Active
N/A fidaxomicin Clostridium difficile infection Pending
N/A naloxagol Management of opioid-induced constipation (OIC). Pending
N/A nivolumab Hodgkin lymphoma Pending
Naglazyme Galsulfase (Drug Plan Submission) Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome) List with clinical criteria and/or conditions Complete
Nerlynx Neratinib ERBB2-positive breast cancer Do not reimburse Complete
Nesina Alogliptin Diabetes mellitus, type 2 Do not list Complete
Neulasta Pegfilgrastim Neutropenia List with clinical criteria and/or conditions Complete
Neupro Rotigotine Parkinson's disease Do not list Complete
Neupro Rotigotine Parkinson’s disease List with clinical criteria and/or conditions Complete